For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Tafinlar + Mekinist is the first and only approved targeted therapy to treat patients with BRAF V600+ NSCLC1,2

Learn more now 

Choose Tafinlar + Mekinist first-line for your patients with unresectable or metastatic melanoma with a BRAF V600 mutation

See powerful and durable results

Offer your patients a convenient oral dosing treatment option1,2

See dosing schedule

OS, overall survival; QOL, quality of life.

References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2. Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 3. Flaherty KT, Davies MA, Grob J, et al. Genomic analysis and 3-year efficacy and safety update of COMBI-d. J Clin Oncol. 2016;34(suppl) [abstract 9502]. 4. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Presented at: European Society for Medical Oncology Annual Meeting; October 7-11, 2016; Copenhagen, Denmark. 5. Schadendorf D, Amonkar MM, Stroyakovskiy D, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51(7):833-840. 6. Grob J-J, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389-1398.